🟠 Moderate Evidence
Hospital admissions related to vitamin B12 deficiency increased by 32% in Brazil between 2016 and 2023, according to analysis of 84 million laboratory tests linked to national health system records, published in Frontiers in Nutrition (2026). The rise spans neurological, cardiovascular, psychiatric, hematologic, and gastrointestinal complications, suggesting vitamin B12 insufficiency may represent a larger clinical burden than commonly recognized across multiple organ systems.
Key takeaways
- B12-related hospitalizations rose 32% over seven years (2016–2023) in Brazil’s national health system, despite routine laboratory testing
- Functional neurological changes can occur even when serum B12 levels remain within currently defined normal ranges, indicating diagnostic thresholds may miss early disease
- Risk patterns in Brazil likely reflect broader patterns in high-income countries where older adults, metformin users, and those with impaired absorption face elevated deficiency risk
Study at a Glance
| Source | Frontiers in Nutrition |
| Study type | Observational analysis of national laboratory and hospitalization records |
| Sample size | 84 million vitamin B12 laboratory tests |
| Population | Brazilian national health system patients, 2016–2023 |
| Country | Brazil |
Vitamin B12-related hospitalizations by system affected
Brazil national health system, 2016–2023 | relative burden across organ systems
Source: Frontiers in Nutrition, 2026 | Brazilian health system administrative data
A rising clinical burden masked by normal test ranges
Vitamin B12 deficiency is traditionally viewed as a niche nutritional condition, yet the scale of the Brazilian data challenges this perception. Between 2016 and 2023, researchers examined 84 million vitamin B12 laboratory tests conducted within Brazil’s national health system and cross-referenced results with hospitalization records, according to analysis published in Frontiers in Nutrition (2026). The 32% increase in B12-related hospital admissions suggests that standard laboratory testing, while routine, may not translate into earlier clinical intervention or prevention of severe downstream complications.
A critical finding emerges from supporting neuroimaging and biomarker research: functional neurological changes can occur even when serum B12 levels fall within currently accepted normal ranges. Published in peer-reviewed literature (2025), these studies demonstrate that threshold-based diagnostic criteria may fail to identify patients at risk of clinically meaningful insufficiency, particularly those approaching the lower boundary of normal. This suggests a diagnostic gap where patients progress from biochemically normal to severely symptomatic without intermediate detection.
Vulnerable populations in high-income countries face similar risk
While the Brazilian analysis is specific to one national health system, the underlying risk factors are globally distributed. In the United States and other high-income countries, average vitamin B12 intake often hovers near minimum dietary requirements, particularly among three overlapping populations: older adults with age-related malabsorption, individuals with impaired gastrointestinal absorption (including those with pernicious anemia or atrophic gastritis), and users of common medications that inhibit B12 absorption or metabolism.
Metformin, a first-line glucose-lowering agent used by millions globally, and proton pump inhibitors, widely prescribed for gastroesophageal reflux, both reduce vitamin B12 absorption. Long-term users of these medications face cumulative deficiency risk, yet routine B12 monitoring is not standard practice in most primary care settings. The Brazilian pattern—where deficiency is detected retrospectively through hospitalization for neurological, psychiatric, or hematologic complications—likely mirrors the trajectory in many developed health systems where preventive screening remains inconsistent.
B12-related hospitalizations increased 32% over seven years in Brazil (2016–2023), spanning neurological, cardiovascular, psychiatric, hematologic, and gastrointestinal diagnoses, suggesting deficiency is diagnosed after complications develop rather than during earlier preventable stages.
— Frontiers in Nutrition analysis of Brazilian national health system (2026)
Diagnostic thresholds and the subclinical disease question
A methodological limitation of the Brazilian study is its observational nature: hospitalization records capture severe outcomes and cannot directly measure subclinical disease in the broader population. However, the scale of the dataset—84 million laboratory tests—and the consistency of the upward trend across multiple organ systems suggest a probable systemic pattern rather than a statistical artifact. For more on how evidence standards shape clinical practice, see our ongoing coverage of clinical updates and diagnostic guidelines.
The parallel finding that neuroimaging studies show functional brain changes at serum B12 levels currently classified as “normal” raises a fundamental question: are existing reference ranges—typically defined by the 2.5th to 97.5th percentile of healthy populations—appropriate for detecting clinically relevant insufficiency? Some researchers propose that a functional B12 threshold (based on biomarkers such as methylmalonic acid and homocysteine) may better predict risk than serum B12 alone, but this remains outside routine diagnostic practice in most health systems.
Implications for clinical practice and health policy
The Brazilian data point toward a missed opportunity for earlier intervention. If B12 deficiency progresses silently—detectable on laboratory tests but clinically unrecognized—until complications warrant hospitalization, the health system bears both the burden of acute care costs and the patient experiences preventable neurological or psychiatric morbidity. For a broader perspective on nutritional epidemiology, explore data-driven health analysis on GMJ News.
Rethinking B12 adequacy in clinical guidelines may require three shifts: (1) risk stratification to identify high-risk populations (older age, medication users, gastrointestinal disease), (2) proactive screening using functional biomarkers rather than serum B12 alone, and (3) lower treatment thresholds in symptomatic or at-risk groups. Such changes would align detection with functional need rather than statistical normality. The evidence base for this approach continues to strengthen, as reflected in emerging health policy discussions around nutritional adequacy standards.
What this means
Frequently asked questions
Why did B12-related hospitalizations increase 32% in Brazil if testing is routine?
The rise suggests that laboratory testing, while common, does not automatically translate into clinical action or early intervention. Patients likely received test results within normal ranges, experienced progressive symptoms unrecognized as B12-related, and were hospitalized only after complications (neurological, psychiatric, or hematologic) became acute. This points to a diagnostic-to-intervention gap in clinical systems.
Can you have B12 deficiency symptoms with a normal serum B12 level?
Yes. Neuroimaging and biomarker research demonstrates that functional neurological changes occur even at serum B12 levels currently defined as normal. This suggests that a single test result does not fully capture tissue-level B12 status. Functional biomarkers such as methylmalonic acid and homocysteine may be more sensitive indicators of true insufficiency.
Is this Brazilian pattern relevant to my country?
The risk factors—aging populations, widespread metformin and proton pump inhibitor use, and variable dietary B12 intake—are global. While the exact hospitalization rate may differ by health system structure and recording practices, the underlying epidemiology of B12 deficiency is relevant across high-income and many middle-income countries. The Brazilian data serve as a clinical signal that many health systems may be missing early disease.
The emerging evidence—from Brazil’s large-scale hospitalization data and from international neuroimaging studies—signals that vitamin B12 deficiency may be more clinically consequential and more commonly under-detected than current practice assumes. As health systems continue to gather population-scale data on outcomes, opportunities will emerge to refine screening protocols and diagnostic thresholds. The question is not whether B12 deficiency matters, but whether current detection methods capture it early enough to prevent harm.
Source: Vitamin B12 deficiency hospitalization trends and biomarker evidence
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
